Globally, many children and newborns with severe infections have virtually no new treatment options. Additionally, there is a high level of resistance existing antibiotics, leading to an increased mortality rate for severe infections.
In collaboration with GARDP, Penta has recently completed recruitment for an observational study (NeoOBS) designed to identify which bacteria causes sepsis in newborns, their resistance patterns and the most frequently used antibiotics to treat the infections. Part of NeoOBS programme is NeoFosfo, a trial aimed at identifying safety of fosfomycine in neonates.
Antimicrobial resistance is responsible for half of all sepsis-related deaths in newborns in hospital. Babies which survive these type of infections face the possibility of neurodevelopment deficits. There is an urgent need to prioritized neonatal infection research in terms of diagnosis, prevention and treatment options for severe neonatal bacterial infections.
Through observational and interventional clinical trials, Penta is committed to preventing multi-resistant severe infections in children and working to optimally manage those infections, improving mortality and clinical outcomes.
Penta has used its years of experience and learning in the field of HIV, and taken this approach into the antimicrobials field. Penta’s approach is unique because Penta works both in infection prevention and treatment. It is through this that Penta can make progress in improving clinical outcomes and reducing children’s mortality worldwide.
The burden of neonatal sepsis is particularly felt in India: incidence and fatality rate are very high if compared to high resource countries. Moreover, causative agents are often multidrug-resistant bugs. Policy makers, researchers, funders must work together to find the answers needed to improve clinical outcome of newborns in low-resource settings.
Penta’s holistic approach to severe infections makes our strategy unique. Penta works both on mother and child, working to prevent mother-to-child transmission, but also on the identification of optimal treatment for infected babies .
Penta is committed to fight antimicrobial resistance, through a network of clinical sites working on observational trials in severe infections and antimicrobial resistance patterns. Observational studies allow the design and implementation of trials aiming to test routinely-used antibiotics as well as identify new antibiotics to optimally treat severe infections in children.